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Summary 
Background  
Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults 
and leads to severe fatigue, significant physical functional impairment, and restricted social 
participation. In this study, we aimed to determine whether cognitive behavioural  therapy 
(CBT) optionally combined with graded exercise compared to standard care alone improved 
the health status of patients with DM1.  
Methods 
In this, prospective 16-month trial, we randomly assigned in a 1:1 ratio, 255 severely fatigued 
adult DM1 patients to CBT compared to standard care. We defined severe fatigue as a score 
of ≥35 on the checklist individual strength, subscale fatigue severity (CIS-fatigue). Patients 
were recruited at four neuromuscular referral centres - with experience in treating DM1 
patients - located in Paris, France, Munich, Germany, Nijmegen, the Netherlands and 
Newcastle, the United Kingdom. Randomisation was performed by local trial staff via a 
central, GCP-compliant, web-based system, developed by the Tayside Clinical Trials Unit. 
CBT focused on addressing reduced initiative, increasing physical activity, optimizing 
interaction with significant others, regulating sleep-wake pattern, addressing pain behaviours 
and beliefs and beliefs about fatigue and DM1. CBT was delivered by experienced and 
specifically trained CBT therapists over a 10-month period in 10-14 sessions, with the 
majority of session given in the first four to five months. A physical therapist supervised 
graded exercise module aimed at increasing physical fitness could be added to CBT, in two 
of the study centres. The primary end point was 10-month change on the DM1-Activ-c scale, 
a disease-specific Rasch-built measure of capacity for activity and social participation that 
has a 0-100 interval range.  Only outcome adjudicators were blind to treatment allocation. 
Statistical analysis of primary outcome of change in DM1-Activ-c score was intention-to-treat, 
utilising mixed effects linear regression models with baseline as a covariate. 
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Findings 
255 patients were randomised between April 2014 and May 2015, 128 to the intervention 
and 127 to standard care alone. At 10 months, the adjusted mean DM1-Activ-c score in the 
intervention group had improved 1·53 points (95% CI -0·14 to 3·20) and had worsened 2·02 
(-4·02 to -0·01) points in the standard care group, with a mean difference in favour of the 
intervention groupof 3.27 points (0·93 to 5·62, p = 0·007). We recorded 244 and 155 adverse 
events (AE); and 24 and 23 serious adverse events (SAE) in the intervention and standard 
care groups, respectively. AE and SAE were distributed equally across groups, with the 
exception of falls occurring more frequently in the intervention group compared to the 
standard care group, 160 versus 72 falls, respectively. In the intervention group, 5 falls 
classified as SAE versus 1 in the standard care group. Most frequently occurring non-fall AE 
and SAE involved cardiac, pulmonary-thoracic or gastro-intestinal systems, and were in the 
latter two often of infectious nature. 
Interpretation 
CBT increased the capacity for activity and social participation in DM1 patients at 10 months. 
With no curative and few symptomatic treatments available, CBT could be considered for use 
in severely fatigued DM1 patients. 
Funding 
Funded by the European Union Seventh Framework Program, under grant agreement 
number 305697 (OPTIMISTIC project); Clinicaltrials.gov number, NCT02118779.  
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Background 
Myotonic dystrophy type 1 (DM1) is an autosomal dominant chronic progressive multi-system 
disorder and the most common form of muscular dystrophy in adults.1 The disease leads to 
significant physical impairment, which in combination with the neuropsychological impacts of 
the condition, results in severely restricted social participation.2-6 No curative treatment 
exists, and evidence for the efficacy of rehabilitative approaches is largely lacking, resulting 
in considerable unmet need for treatment that aims to improve health status.7 
A DM1-specific model of factors determining health status was empirically derived from the 
findings of our longitudinal study.8 This model predicts that improvement of patient reported 
health status can be achieved by addressing reduced initiative, optimizing physical activity, 
and alleviating experienced fatigue. Previous studies have shown that fatigue is a highly 
prevalent and debilitating symptom in DM1.9,10 Cognitive behavioural therapy (CBT) has 
been found effective in relieving fatigue in chronic fatigue syndrome and type 1 diabetes.11,12 
In facioscapulohumeral muscular dystrophy, CBT reduced fatigue and increased objective 
activity (as measured with actometry) and social participation.13 In addition, there is 
accumulating evidence supporting the beneficial effects of low-to-moderate-intensity strength 
and aerobic exercise training and an active lifestyle in neuromuscular diseases.14,15 
Nevertheless, recent reviews conclude that studies evaluating graded activity in 
neuromuscular diseases are limited in number and quality, and that there is a need for 
disease-specific, randomised, controlled trials investigating the effect on health status.14,16 
We therefore conducted a large international, multi-center, randomised trial to determine 
whether CBT plus optional graded exercise improved health status of patients with DM1 
compared to standard care alone.17  
Methods 
Study design and participants 
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Four European clinical sites (Munich, Germany; Nijmegen, the Netherlands; Newcastle, UK; 
Paris, France) collaborated in this study. Eligible patients with a confirmed genetic DM1 
diagnosis who provided written informed consent were randomly assigned to study groups. 
There were up to five assessment visits: eligibility screening followed by baseline, five, 10 
and 16 months post-randomisation, with the primary outcome being measured at 10 months. 
The study protocol has previously been published.17  
We recruited DM1 patients aged 18 years and older who were severely fatigued as 
measured by the checklist-individual strength subscale fatigue (CIS-fatigue, score ≥35)18, 
able to walk independently (walking aids permitted) and undergo trial interventions (Table S1 
in the Web Extra material, available at thelancet.com). The study was approved by the 
institutional review boards at each of the four clinical sites and conducted in accordance with 
the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines. Patients 
were recruited by invitation via DM1 registries, from clinics via their treating neurologists, or 
independently through study awareness by patient organizations. We invited the patients’ 
caregiver to participate, as described previously.17 
Randomisation and masking 
Eligible patients were randomised in a 1:1 ratio via a central, GCP-compliant web-based 
system called the Tayside Randomisation System (TRuST) developed by the Tayside 
Clinical Trials Unit at the University of Dundee, UK. Trials Unit statisticians and data 
management staff programmed TRuST to implement the randomisation described in the 
OPTIMISTIC protocol namely that randomisation was stratified by site (location of inclusion) 
and minimized for baseline DM1 severity (as assessed by the muscular impairment rating 
scale (MIRS)) and for baseline involvement of a caregiver.19 Immediate family members (i.e 
parents, children, siblings) were allocated as a cluster to avoid treatment contamination.  
Only outcome adjudicators were blind to treatment allocation, patients could not be blinded to 
allocation. Outcome adjudicators were instructed to refrain from interactions with the patient 
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that could disclose treatment allocation. During therapy, patients were discouraged from 
disclosing their treatment allocation to outcome adjudicators. 
Study procedures and interventions    
Patients in the comparison group received standard care applicable to each individual’s 
country (table S2 in the Web Extra material). In addition to receiving standard care, all 
patients randomised to the intervention arm also received CBT (details in table S3 in the 
Web Extra material).17 In a process of shared-decision making on the basis of therapist 
assessment and questionnaire evaluation, CBT was customized to the individual participant 
by the selection of one or more appropriate treatment modules: regulating sleep-wake 
pattern, compensating for a reduced initiative, formulating helpful beliefs about fatigue and 
DM1, optimizing social interactions and coping with pain. In addition, CBT included a graded 
activity module for every patient. To ensure a high degree of treatment integrity, CBT was 
manual-based, delivered by experienced CBT therapists with extensive training prior to start 
of the trial, and monitored during the delivery of the intervention (table S3). The treatment 
manual is available upon request (see table S3 for details). We evaluated treatment integrity 
of CBT as given during the conduct of the trial by means of evaluation of therapist-recorded 
case report forms from each session from every CBT participant, and by the assessment of 
audio records of CBT sessions that were recorded during the intervention (details in Web 
Extra material, S8).  
If considered appropriate through a process of shared-decision making between CBT 
therapist and participant, a graded exercise module supervised by a physical therapist could 
optionally be added to CBT in the participants randomised to intervention (table S4 in the 
Web Extra material). Although we planned this in all four centres, differences in standard 
care meant we could implement the graded exercise in two out of four sites (Nijmegen and 
Newcastle). As it was not possible to offer the graded exercise module as an option within 
the French and German care pathways for DM1 patients, this constituted a protocol 
 Okkersen { PAGE   \* MERGEFORMAT } 
 
 
 
deviation, as listed in the Web Extra material. The graded exercise module constitutes a 
structured exercise program aimed at increasing physical fitness. The program was 
individually defined, but targeted incorporating moderate intensity exercises (e.g. walking, 
cycling, jogging or dancing) for at least half an hour, three times a week. The graded 
exercise module was given during the intervention period. The overall intervention (i.e. CBT 
and GET when applicable) was scheduled for a duration of 10 months, starting directly after 
randomisation. Patients were to receive 10-14 sessions of CBT (no specific duration 
specified), with the majority delivered in the first 4-5 months. We planned for a minimum of 5 
face-to-face sessions, but other communication formats, such as telephone or video calls 
were acceptable. 
Onsite and remote visits to assess protocol compliance and adherence to good clinical 
practice  guidelines were performed during the conduct of the study by local trial staff and by 
staff from the coordinating Trials Unit in Dundee, United Kingdom. 
Outcomes measures 
The primary outcome was the change in DM1-Activ-c at the end of the 10-month intervention 
period (Web Extra material, table S5). The Rasch-built DM1-Activ-c is a DM1 specific patient-
reported outcome measure of capacity for activity and social participation.20,21 The DM1-
Activ-c with a 0-100 score range is the updated version of the DM1-Activ scale that had a 0-
40 score range. We based our power calculation on the DM1-Activ and planned it to be the 
primary outcome measure. However, deviating from the study protocol (Web Extra – list of 
protocol deviations), we decided to use the DM1-Activ-c after criticism of the DM1-Activ had 
led to the publication of an updated version that was available to us before the start of the 
study.21 
Predefined secondary outcome measures categorized into five groups were collected: 
physical activity and exercise capacity: six-minute walk test (6MWT) with Borg scale 
assessment, myotonic dystrophy health index (MDHI), physical activity measured with an 
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accelerometer (Web Extra S9); fatigue and sleepiness: fatigue and daytime sleepiness scale 
(FDSS), CIS-fatigue; quality of life: individualised neuromuscular quality of life questionnaire 
(InQoL); depressive symptoms: Beck-depression inventory-fast screen (BDI-fs) ;and 
cognition: Apathy evaluation scale – clinician version (AES-c) and Stroop test interference 
score (Table S5 and study protocol paper).17 The Borg scale is a subjective measure of 
perceived exertion taken immediately after the 6MWT; we utilised the 0-10 scale, as 
recommended previously.22 For accelerometry, we calculated mean 24h activity levels, and 
levels of activity during the 5 most active and 5 least active hours of the day. Adverse events 
(AE) and serious adverse events were reported continuously during the study and reviewed 
at each study visit.17 
Statistical analysis 
The agreed statistical analysis plan (SAP) was made publicly available at www.optimistic-
dm.eu prior to completion of the study (available from: www.optimistic-dm.eu: 
http://www.optimistic-dm.eu/images/com_projectfork/progress/OPTIMISTIC_SAP.pdf). 
Analyses were done by the trial statistician (A.H.), and checked by a second statistician 
(P.T.D). Based on a minimum clinically important mean difference of 1.4 on the 40-item 
DM1-Activ scale, a standard deviation of 3.5, effect size = 0.4, 80% power at the 5% 
significance level, a total sample size of 200 patients was required.17 We accounted for the 
potential of clustering of DM1 family members in identical treatment arms by inflating the 
sample size to 208. The trial was also fully powered for 6MWT, a secondary outcome 
assessing exercise capacity.23 The recruitment target was set at 296 to allow for a potential 
drop-out rate of up to 30% based on previous pilot studies in DM1 patients.24 Full details of 
the sample size calculations have been described previously (see full trial protocol and 
SAP).17 
The primary outcome analysis was conducted according to the principles of intention-to-treat 
as outlined on the ICH E9 ‘Statistical Principles for Clinical Trials’. We utilized mixed effects 
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regression models with baseline scores as a covariate to assess the change in DM1-Activ-c 
score at 10 months. Priorly, the raw sum scores of the DM1-Activ-c scale were translated 
into a log-odds units (logit) scale, using the Rasch-model.25 Since logits are difficult to 
interpret intuitively, the logits were converted into a centile metric score with values ranging 
from 0 (most severe activity and social participation limitations) to 100 (no activity and social 
participation limitations). The mixed effects models included the intervention (as a binary 
variable), age and the minimisation variables (MIRS score and involvement of the caregiver 
at baseline (as a binary variable) as fixed effects and site as random effect. Random effects 
were included for each subject in the repeated measures analyses, as well as for correlation 
within family group. Results are presented as model-derived means and 95% CIs. Planned 
subgroup analyses were carried out by testing for a subgroup by intervention interaction, as 
detailed previously (SAP).17 Predefined subgroups were implemented for number of CBT 
sessions attended, clinical site, severity of DM1 as defined by MIRS score, involvement of 
the caregiver, age, sex, and addition of the graded exercise module to CBT. All these 
analyses were repeated for all the secondary outcome measures. In addition, we performed 
post-hoc repeated measures analysis for primary and secondary outcomes at all timepoints. 
We used SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA) for statistical 
analyses. 
Role of the funding source 
The funder of this trial had no role in the study design, data collection, analysis, interpretation 
of data, writing the report, or decisions regarding when to submit publications. All authors 
were involved in design and/or conduct of the study and in the preparation of the manuscript. 
All authors had full access to all data in the study and all authors take full responsibility for 
the decision to submit the paper for publication. They attest to the accuracy, completeness of 
the data and analyses.  Researchers wishing to get access to the data collected in the 
OPTIMISTIC study are requested to contact the last author at 
Baziel.vanEngelen@Radboudumc.nl and sign a data access agreement. Requests for 
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access will be reviewed by a panel consisting of one representative of the 4 clinical sites 
each, chaired by Baziel van Engelen. 
Results 
Study patients 
Patients were randomised between April 2, 2014 and May 29, 2015, with follow-up 
continuing until October 17, 2016 when the last patient underwent the 16-month assessment. 
A total of 255 patients underwent randomisation, 128 patients were allocated to the 
intervention and 127 allocated to standard care alone (Figure 1). Baseline characteristics 
between both groups were similar (Table 1). Thirty-three out of the 128 (26%) patients 
randomised to intervention were involved in the additional graded exercise module. There 
was no cross-over from standard care to intervention; four patients randomised to CBT 
considered it too much burden and did not attend any sessions, but remained in the trial. At 
10 months, 231 (91%) patients completed the primary outcome evaluation, with similar 
losses to follow-up across both groups. By the end of the study at 16 months, 225 (88%) 
patients remained in the trial, with a total of 14 formal withdrawals in the intervention group 
and 16 in the standard care group. The reasons given for trial withdrawal included the burden 
of travelling to clinical site for trial measurements and the number of questionnaires to be 
completed at each visit. 
Protocol deviations 
During the conduct of the study, some protocol violations occurred; these are listed in the 
Web Extra Material available at thelancetneurology.com. Most importantly, we made use of 
DM1-Activ-c scale, an updated version of the DM1-Activ scale. Whereas the original scale 
DM1-Activ was published in 2010, criticism led to its revision and publication of an updated 
version in 2015.20,21 As DM1-Activ-c was available before inclusion of the first patient, this 
updated version was used in the trial.21 In addition, although we planned to offer graded 
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exercise in all centres, we were only able to provide graded exercise in Nijmegen and 
Newcastle, thus limiting the availability of this add-on to CBT. Other deviations that occurred 
are listed in the Web Extra material. 
Primary and secondary outcomes 
After 10 months, the DM1-Activ-c scale, demonstrated an adjusted mean increase of 1·53 
(95%CI: -0.14 to 3.20) points in the CBT group compared with an adjusted mean decrease of 
2·02 (95%CI: -4.02 to -1.01) points in the standard care group (Table 2). In our predefined 
primary outcome analysis of DM1-Activ-c, there was a difference between both groups of 
3·27 points (95%CI: 0·93 to 5·62, p = 0·007) in favour of the intervention group at 10 months. 
Differences at 10 months in favour of CBT were also found for total distance on 6MWT, the 
fatigue and daytime sleepiness scale (FDSS), CIS-fatigue and daily activity levels (24 hours 
and most active 5 hours, average of seven consecutive days) measured by accelerometry 
(Table 2). Although MDHI and InQoL-quality of life scores decreased from baseline to 10 
month follow-up in the intervention and standard care group, no significant between-group 
differences were found. Three secondary outcomes measures (i.e. apathy evaluation scale, 
Stroop interference, BDI-FS), demonstated no change over time and no between-group 
differences (Table 2).  
With one exception (i.e. the effect of site on FDSS at 10 months), pre-specified subgroup 
analyses yielded no significant interactions of age, sex, site, MIRS, involvement of caregiver, 
number of CBT sessions or the addition of a supervised graded exercise module to CBT on 
primary or secondary outcomes at 10 months, after Bonferroni correction for multiple testing 
(Web Extra tables S6a and S6b). In a post-hoc analysis, scores on the CIS-fatigue scale at 
10 months had decreased to <35 in 47 out of 112 (42%) and 20 out of 106 (19%) patients in 
the intervention and standard care groups, respectively. 
For DM1-Activ-c, post-hoc repeated measures analysis demonstrated improved scores 
compared to baseline in the intervention group at five months, maximizing at 10 months and 
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continuing until 16 months, although there was a drift towards the standard care group 
scores at 16 months (Web Extra table S7). The difference between intervention and standard 
care groups over all time periods was in favour of the intervention (p = 0·004). Similar 
temporal patterns were seen for 6MWT, MDHI, FDSS, CIS-fatigue, accelerometry (mean 24 
hours and highest 5 hours of activity) and InQoL (quality of life domain) (Web Extra table S7). 
Of these, 6MWT, FDSS, CIS-fatigue and accelerometry demonstrated significant between-
group differences. BDI-fs and AES-c scores were relatively stable across timepoints and we 
detected no significant between-group differences. Although Stroop interference scores 
improved with time in both groups, no between-group differences were found (Web Extra 
table S7). 
Adverse events  
We recorded a total of 399 adverse events (AE) in 128 subjects, with 244 events in 65 
patients in the intervention group compared to 155 events in 63 patients in the standard care 
group (Table 3). A total of 226 (56·6%) AE were related to falls, 155 in the intervention and 
71 in the standard care group. 51 AE (12·8%) were related to infections and infestations, 32 
in the intervention versus 19 in the standard care group (table 3), these AE comprised mostly 
upper respiratory tract infections, influenza and infections in the oral cavity. We recorded 5 
and 12 AE related to the respiratory tract, thorax and mediastinum, in intervention and 
standard care group, respectively. All other AEs were distributed equally between groups 
(table 3). A total of 47 serious adverse events (SAE) occurred in 34 patients during the 
conduct of the study (Table 4). SAE occurred with similar frequency in the intervention group 
and the standard care group; 24 versus 23 events in 19 and 15 patients, respectively. 
Distribution of SAE across both groups was similar, with the exception of SAE related to falls, 
which occurred more frequently in the intervention group (five versus one). 
Discussion 
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The multi-system and progressive nature of DM1 leads to severe physical impairment, 
restricted social participation and premature death, yet no FDA approved therapies are 
available.3,26-28 Experienced fatigue is a highly prevalent and debilitating symptom that has 
been shown to have the greatest impact on the lives of patients with DM1.10 Data from this 
prospective trial, in which severely fatigued adult DM1 patients were randomly assigned to 
CBT compared to standard care, show that CBT by month 10 increased capacity for activity 
and participation as measured with the DM1-Activ-c scale. In addition, CBT was superior to 
standard care on several secondary outcome measures of experienced fatigue (CIS-fatigue 
and FDSS), exercise capacity (6MWT), and objective physical activity as measured with 
accelerometry. At 10 months, improvements in outcome measures for quality of life (InQoL – 
quality of life subdomain) and disease burden (MDHI) were not significantly different between 
groups. It should be noted the trial was not powered for any of the secondary outcome 
measures except the 6MWT.  
In DM1, few, if any fully validated disease-specific outcome measures exist, complicating the 
conduction of clinical trials in DM1.29 The sensitivity to change for DM1-specific outcome 
measures, including the DM1-Activ-c scale, was unknown during the design phase of the 
trial. Nonetheless, we selected the best outcome measures available at that time, after 
careful consideration in our consortium and based on consensus literature in the international 
DM1 community.30 We think the clinical relevance of a 3·27 point difference on the DM1-
Activ-c at 10 months, is supported by concurrent changes in the secondary outcome 
measures in favour of the intervention group that measured activity, exercise capacity, and 
fatigue. In particular, the 26·5 meter difference between groups at 6MWT at 10 months would 
be beyond the minimal clinically important change in DM1, which was previously defined as a 
6% change in walking distance between assessments.23 In the intervention group alone, the 
increase in walking distance from 389 to 421 meters means an increase of approximately 
8%. The outcomes at follow-up showed a tendency for a decrease of the beneficial effects of 
CBT over time. We suggest that booster sessions of CBT may help to maintain beneficial 
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effects to their maximum.31 Intriguingly, despite the increase in activity and exercise capacity, 
our study did not demonstrate changed levels of apathy. This may be explained by the 
nature of the CBT module dealing with apathy, in which we aimed to teach patients how to 
compensate for reduced initiative (but did not aim to increase levels of initiative per se). 
Subgroup analysis demonstrated that treatment effects were largely independent of age, sex, 
clinical site, the addition of a graded exercise supervised by a physical therapist, MIRS score 
at study entry or involvement of a caregiver. This means that despite differences in health-
care systems, favourable effects can be achieved in different settings. The lack of additive 
benefit with the addition of the graded exercise module means that CBT alone is capable of 
increasing activity levels and exercise capacity in DM1 patients. However, it should be noted 
that the group of patients that were involved with the graded exercise module was relatively 
small, which means care is needed when interpreting this result. Moreover, our results do not 
at all preclude a beneficial effect of exercise therapy per se (i.e. without CBT) in DM1 
patients, that was suggested in previous literature.32,33 Finally, we are suprised to find that the 
involvement of a caregiver with the study did not affect outcome, as we had expected better 
outcomes through supportive effects when caregivers were involved with the study.  
With regards to CBT safety, the equal distribution of SAE across groups is reassuring. 
However, falls were more frequent in the intervention group. Falls are a common 
complication in natural DM1 history, but the increased risk of less serious falls linked to the 
intervention underlines the importance of monitoring and where possible addressing this 
issue in clinical practice and future clinical trials.34,35 Furthermore, patients may underreport 
DM1 related complications, such as falls, as a result of reduced disease awareness.36 The 
excess fall frequency in the CBT group might be partly explained by a better recall resulting 
from more frequent contacts with trial staff (i.e. CBT therapists). Another explanation is a true 
increase in fall frequency as a result of spending more time being active, during which time a 
higher number of falls may occur. Other factors that we did not evaluate, such as the 
occurence of cataracts, may have influenced our results. It should be noted that the total 
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number of falls (i.e. 226) recorded in our study is relatively low in comparison with the recent 
Swedish study reporting falls in DM1 (which reported more than 200 falls occuring over a 1 
year period in 43 DM1 patients). This could be due to differences in fall evaluation and the 
fact that less severely affected patients (as defined by MIRS score) were excluded from the 
other study.35 Nevertheless, it seems reasonable to conclude that increasing activity levels in 
people with DM1 will lead to more falls, though most are minor.  Balancing this potential 
harm against the potential benefit of increased activity levels needs to be a shared decision 
between patient, carers and health professionals.  
This trial was characterized by high recruitment and low drop-out rates, in contrast to a 
previous study in this patient population.24 The selection of severely fatigued DM1 patients 
increases the generalisability of our results, as a previous study found severe fatigue in 74% 
of otherwise unselected DM1 patients, using the same instrument and cut-off score (i.e. CIS-
fatigue ≥35).9   
The trial has some limitations. The lack of information on respiratory muscle involvement can 
be considered a limitation of our study, as this may influence fatigue, physical activity and 
exercise capacity. Possibly, more frequent contact with trial staff for patients in the 
intervention group might have led to desirability bias: more desirable answers on patient-
reported outcome measures in comparison with the standard care group. Nevertheless, the 
statistically significant differences on objective physical activity, as measured with 
accelerometry and the six-minute walk test, a measure of exercise capacity, argue against 
desirability bias as a sole explanation for our favourable results. In common with other 
studies employing accelerometry, there were missing data.37,38 However, the quantity of 
missing data did not differ significantly between groups; with comparable reasons of 
noncompliance and device loss or failure, to those reported in the literature.37,38  
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Figure 1. Screening, randomisation, treatment, and follow-up in the trial 
Abbreviations: CIS-fatigue: checklist individual strength, subscale fatigue 
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Table 1. Characteristics of patients at study entry 
Characteristic* Intervention group 
(N = 128) 
Standard care group 
(N = 127) 
Clinical characteristics 
Age in years - mean 44·8 ± 11·7 46·4 ± 11·3 
Sex male/female – no. (%) 70 / 58 (55% / 45%) 67 / 60 (53% / 47%) 
BMI in kg/m2 26·5 ± 6·1 26·2 ± 5·3 
Age at disease onset in years 24·9 ± 12·6 26·2 ± 13·3 
Duration of disease in years 19·7 ± 9·6 19·4 ± 10·5 
Participants with a family member in the study 
– no. (%) 
12 (9%) 18 (14%) 
Location of enrollment – no (%) 
- Paris, France 
- Munich, Germany 
- Newcastle, United Kingdom 
- Nijmegen, the Netherlands 
 
37 (29%) 
33 (26%) 
25 (20%) 
33 (26%) 
 
34 (27%) 
33 (26%) 
27 (21%) 
33 (26%) 
Years of education 14·0 ± 3·5 14·6 ± 4·2 
MIRS – median, ranges 3 (1 to 5) 3 (1 to 5) 
Use of walking aids – no. (%) 
- Walking with aids† 
- Intermittent use of wheelchair† 
 
23 (18%) 
18 (114%) 
 
25 (20%) 
20 (16%) 
 Okkersen { PAGE   \* MERGEFORMAT } 
 
 
 
CIS-fatigue 44·9 ± 5·92 44·9 ± 6·3 
BDI-FS 4·3 ± 3·1 4·0 ± 3·2 
Involvement of caregiver† – no. (%) 56 (44%) 50 (39%) 
Employment – no. (%) 46 (36%) 49 (39%) 
Concomitant condition and therapy 
Presence of cardiac condition – no. (%) 
- Cardiac condition – not further specified 
- Cardiac arrhythmia or conduction defect 
- Cardiomyopathy 
 
  6 (5%) 
37 (30%) 
  3 (2%) 
 
  2 (2%) 
41 (33%) 
  3 (2%) 
Presence of pacemaker and/or ICD – no. (%) 23 (18%) 21 (17%) 
Regular use of assistive ventilatory device – 
no. (%) 
 
23 (18%) 
 
16 (13%) 
Medication – no. (%) 
- Psychostimulant drug use (total) 
- Modafanil 
- Ritalin  
- Antidepressants 
 
25 (20%) 
20 (16%) 
2 (2%) 
3 (2%) 
 
25 (20%) 
19 (15%) 
1 (1%) 
5 (4%) 
Genetics 
Estimated progenitor CTG repeat length – 
median (range) 
 
233·0 (50 to 789) 
 
211·5 (61 to 726) 
Modal CTG repeat length – mean, median   
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(SD) 508·9, 482·0 ± 276·1 512·3, 470·0 ± 292·2 
 
Table 1. Characteristics of patients at study entry  
* Plus-minus values are observed means ± SD.  
† one missing value for walking with aids, intermittent wheelchair use, involvement of the caregiver.  
Abbreviations: BMI: body mass index, MIRS: muscular impairment rating scale, CIS-fatigue: checklist 
individual strength, subscale fatigue, BDI-FS: Beck depression inventory fast-screen, ICD: implantable 
cardioverter-defibrillator  
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Table 2. Changes in primary and secondary outcomes between baseline and 10 months 
 
 Intervention group (N=128) Standard care group (N=127) Mean (95%CI) difference between 
groups 
 N Mean (SD) 
Unadjusted 
Mean change 
(95%CI) from 
baseline 
Adjusted* 
N Mean (SD) 
Unadjusted 
Mean change 
(95%CI) from 
baseline 
Adjusted* 
Adjusted* p-value 
Primary Outcome 
DM1-Activ-c score [higher is beneficial] 
Baseline 128 61·22 (17·35)  127 63·00 (17·35)    
10 months 115 63·92 (17·41) 1·53 (-0·14 to 3·20) 116 60·79 (18·49) -2·02 (-4·02 to -0·01) 3·27 (0·93 to 
5·62) 
0·007 
Secondary Outcomes∫ 
Total distance (m) in 6 MWT [higher is beneficial]; end-of-test BORG score [lower is beneficial]& 
Baseline 
6MWT 
 
128  
389·29 (123·20) 
 
 127  
400·69 (119·74) 
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BORG 4·56 (2·28) 4·58 (2·14) 
10 months 
6MWT 
 
 
BORG 
111  
420·65 (134·84) 
 
 
4·22 (2·01) 
 
22·61 (10·60 to 
34·61) 
 
-0·21 (-0·59 to 
1·76) 
 
99  
401·10 (133·49) 
 
 
4·60 (2·05) 
 
-4·39 (-14·49 to 
5·72) 
 
0·235 ( -0·17 to 1·79) 
 
26·5 (11·1 to 
41·8) 
 
-0·42 (-0·89 to 
0·06) 
 
0·0009 
 
 
0·083 
 
MDHI score [lower is beneficial] 
Baseline 128 37·49 (18·33)  127 35·64 (16·08)    
10 months 112 31·78 (19·35) -5·30 (-7·44 to -
3·15) 
106 33·05 (17·72) -2·07 (-4·36 to 0·22) -2·35 ( -5·35 to 
0.65) 
0·126 
Accelerometry (ENMO) - Mean (24h) physical activity† [higher is beneficial] 
Baseline 128 19·92 (9·53)  127 21·33 (12·72)    
10 months 88 21·22 (9·91) 0·977 (-0·292 to 
2·247) 
76 19·32 (8·85) -2·192 (-3·831 to -
0·554) 
3·23 (1·47 to 
5·00) 
0·0005 
Accelerometry (ENMO) - Mean (most active 5 hours) physical activity† [higher is beneficial] 
Baseline 128 48·80 (26·19)  127 51·01 (34·56)    
10 months 88 53·60 (29·93) 3·439 (-0·897 to 76 47·21 (24·93) -3·897 (-8·366 to 8·36 (2·62 to 0·005 
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7·776) 0·572) 14·10) 
Accelerometry (ENMO) - Mean (least active 5 hours) physical activity† 
Baseline 128 3·86 (0·79)  127 4·29 (2·38)    
10 months 88 3·88 (0·78) 0·038 (-0·142 to 
0·217) 
76 3·80 (0·66) -0·541 (-1·154 to 
0·073) 
0·181 (-0·059 to 
0·422) 
0·141 
FDSS score [lower is beneficial] 
Baseline 128 45·87 (9·72)  126 46·52 (11·54)    
10 months 109 38·38 (10·27) -7·44 (-9·20 to -
5·68) 
104 43·22 (10·78) -3·50 (-5·16 to -1·84) -4·15 (-6.30 to -
2.00) 
0·0002 
CIS-fatigue score [lower is beneficial] 
Baseline 128 44·89 (5·92)  127 44·88 (6·34)    
10 months 113 36·27 (10·91) -8·38 (-10·29 to -
6·46) 
106 40·62 (8·46) -4·34 (-5·82 to -2·85) -3·93 (-1·58 to -
6·28) 
0·001 
InQoL – QoL domain score [lower is beneficial] 
Baseline 128 78·14 (31·94)  127 72·72 (34·82)    
10 months 113 69·21 (35·95) 
 
-8·15 (-12·96 to -
3·34) 
105 70·26 (34·80) -2·27 (-8·00 to 3·47) -4·52 (-11·35 to 
2·31) 
0·196 
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BDI-FS‡ score [lower is beneficial] 
Baseline 128 4·31 (3·10)  127 4·03 (3·15)    
10 months 110 4·06 (3·44) -0·330 (-0·91 to 
0·241) 
105 3·60 (3·14) -0·277 (-0·794 to 
0·240) 
0·064 (-0·644 to 
0·772) 
0·859 
AES-c score [lower is beneficial] 
Baseline 128 38·87 (9·07)  127 37·33 (8·65)    
10 months 109 36·31 (8·47) 0·74 (-0·57 to 2·04) 103 37·24 (9·84) -0·41 (-1·73 to 0·90) 0·63 (-0·98 to 
2·25) 
0·444 
Stroop interference score‡ [lower is beneficial] 
Baseline 128 92·19 (72·26)  127 90·27 (51·99)    
10 months 115 73·95 (40·15) -16·093 (-26·815 to 
-5·370) 
105 77·75 (51·41) -9·995 (-17·127 to -
2·863) 
-0·035 (-0·115 
to 0·045) 
0·389 
 
Table 2. Changes in Primary and secondary outcomes between baseline and 10 months 
* Adjusted for baseline value, MIRS, site, caregiver involvement and age.  
† As measured with accelerometry – unit measure total ENMO.  
‡ Log-transformed in mixed model.  
∫ Abbreviations: 6MWT: six-minute walk test; AES-c: apathy evaluation scale, clinician version; BDS-FS: Beck depression inventory – fast screen; CIS: 
checklist individual strength; FDSS: fatigue and daytime sleepiness scale; InQoL: individualized neuromuscular quality of life; MDHI: myotonic dystrophy 
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health index – total score; Stroop interference: Stroop color-word interference test 
& 0-10 BORG scale 
For score range as outcome measures, please refer to supplemental table S5. 
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Table 3. Adverse events 
 
SOC classification Intervention group 
N = 128 
Standard care 
Group 
N = 127 
All patients 
N = 255 
Blood and lymphatics 0 [0] 2 [2] 2 [2] 
Cardiac 4 [4] 2 [2] 6 [6] 
Ear and labyrinth 0 [0] 1 [1] 1 [1] 
Eye disorders 1 [1] 1 [1] 2 [2] 
Gastro-intestinal 7 [5] 3 [3] 10 [8] 
General disorders 6 [6] 6 [6] 12 [12] 
Immune system 0 [0] 1 [1] 1 [1] 
Infections and infestations 32 [24] 19 [15] 51 [39] 
Injury, poisoning and procedural 
complications 
- Falls 
162 [46] 
 
155 [40] 
81 [39] 
 
71 [33] 
243 [85] 
 
226 [73] 
Investigations 1 [1] 1 [1] 2 [2] 
Metabolism and nutrition 1 [1] 0 [0] 1 [1] 
Muskuloskeletal and connective 
tissue 
14 [14] 12 [9] 26 [23] 
Neoplasm 1 [1] 0 [0] 1 [1] 
Nervous system 7 [7] 9 [8] 16 [15] 
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Psychiatric 0 [0] 2 [2] 2 [2] 
Reproductive system and breast 1 [1] 0 [0] 1 [1] 
Respiratory thoracic mediastinal 5 [5] 12 [9] 17 [14] 
Skin subcutaneous 1 [1] 0 [0] 1 [1] 
Vascular disorders 1 [1] 3 [3] 4 [4] 
Total number of events 244 [65] 155 [63] 399 [128] 
Table 3. Adverse events 
Adverse events were classified according to System Organ Class (SOC) adverse event terminology.15 
Non occurring AE from the SOC list are not listed. Listed are the numbers of AE that occurred, 
followed by the number of patients in whom these occurred in brackets. 
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Table 4. Serious adverse events 
 Intervention group 
(N = 128) 
Standard care group 
(N = 127) 
All patients 
(N = 255) 
Total falls 5 [5] 1 [1] 6 [6] 
Fall 1 [1] 0 [0] 1 [1] 
Fall with fracture 
(extremity) 
1 [1] 0 [0] 1 [1] 
Fall with suspected or 
actual cranial trauma 
3 [3] 1 [1] 4 [4] 
Total pulmonary and 
non-cardiac chest 
5 [5] 5 [5] 10 [10] 
Pneumonia 3 [3] 3 [3] 6 [6] 
Chest Infection 1 [1] 0 [0] 1 [1] 
Pulmonary embolism 0 [0] 2 [2] 2 [2] 
Pneumothorax 1 [1] 0 [0] 1 [1] 
Total cardiac 5 [4] 6 [4] 11 [8] 
Myocardial infarction 1 [1] 2 [2] 3 [3] 
Cardiac arrest 1 [1] 0 [0] 1 [1] 
Atypical chest 
complaints 
2 [2] 1 [1] 3 [3] 
Tachycardia 0 [0] 2 [1] 2 [1] 
Arrhythmia 1 [1] 0 [0] 1 [1] 
Pacemaker installation 0 [0] 1 [1] 1 [1] 
Total gastro-
intestinal  
6 [5] 5 [3] 11 [8] 
Constipation 0 [0] 2 [1] 2 [1] 
Dysphagia 0 [0] 1 [1] 1 [1] 
Gallstone attack 1 [1] 1 [1] 2 [2] 
Bile cystitis 1 [1] 0 [0] 1 [1] 
Peptic Ulcer 0 [0] 1 [1] 1 [1] 
Volvulus 1 [1] 0 [0] 1 [1] 
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GI malignancy (liver) 1 [1] 0 [0] 1 [1] 
Ulcerative colitis 1 [1] 0 [0] 1 [1] 
Abdominal pain – 
unknown etiology 
1 [1] 0 [0] 1 [1] 
Total other 3 [3] 6 [5] 9 [8] 
Extremity fracture – not 
related to falls 
1 [1] 1 [1] 2 [2] 
Urinary tract infection 0 [0] 1 [1] 1 [1] 
Vertigo 0 [0] 1 [1] 1 [1] 
Headache of severe 
intensity 
0 [0] 1 [1] 1 [1] 
Leg pain – unknown 
etiology 
0 [0] 1 [1] 1 [1] 
Back pain - lumbago 1 [1] 0 [0]  1 [1] 
(Epileptic) seizure 1 [1] 0 [0] 1 [1] 
Wound dehiscence 0 [0] 1 [1] 1 [1] 
Overall Total SAE 24 [19] 23 [15] 47 [34] 
Table 4. Serious adverse events 
Number of adverse events and serious adverse events occurring up to 14 days after the final visit (16 
months after baseline), followed by number of patients in whom these occurred in brackets. The 
number in brackets do not always sum up to the totals presented as a consequence of some patients 
that had multiple SAE.  
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List of protocol deviations 
 
1. Primary outcome measure  
We used the DM1-Activ-c, an updated version of the DM1-Activ scale as primary outcome measure. Whereas 
the original scale DM1-Activ was published in 2010, criticism led to its revision and publication of an updated 
version in 2015.1,2 As DM1-Activ-c was available before inclusion of the first patient, this updated version was 
used in the trial.2 Note that the power calculation was based on the DM1-Activ metric scale from 0 to 40, 
whereas the DM1-Activ-c metric scores range from 0 to 100. The University of Maastricht developer of DM1-
Activ (both versions) considers a 1 point difference on the 0 to 40 scale to be equivalent to 2·5 points on the 0 to 
100 scale. We think the power calculations would not have been affected by the choice of the 0-100 instead of 
the 0-40 scale, as the MCID would be expected to change accordingly. 
2. Graded exercise 
We planned to offer the graded exercise component of the program across all four clinical sites. However, due to 
preexisting regular weekly physiotherapy as part of national standard of care in Germany and France, the 
program was eventually offered in two out of four sites (Newcastle and Nijmegen). The graded exercise 
component commenced only once the patient successfully increased his or her level of physical activity 
(walking) during the graded activity program of the CBT and was interested in more vigorous activity. Our 
statistical analysis plan included a subgroup analysis to look at outcomes in those who did and did not have 
graded exercise, as well as investigating the effect of site. 
3. Blinding 
The original protocol stated that all study outcome measures would be collected by staff blind to allocation of 
patients.3 Due to logistical and staffing constraints, this was not always possible in Newcastle. Our statistical 
analysis plan investigated the effect of site. 
4. InQoL versions 
The individualized neuromuscular quality of life questionnaire (InQoL) was a secondary outcome measure.3 Due 
to a logistical error, the clinical site Nijmegen used a different version of the InQoL (that is, version 1.2 – Dutch 
translated version) than the other three clinical sites (that is, version 2.0). Both contain the items required to 
calculate the quality of life subscore of the InQoL.  
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5. ADL assessment 
In our protocol paper, we listed activities of daily living (ADL) assessment as a secondary outcome measure 
(protocol paper, page 7/19). However, we did not include outcome measures that directly measured this (see 
Trial Measurement Outcome Schedule, protocol paper, page 17/19). In fact, we simply forgot to delete it from 
the list.  
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Table S1. Inclusion- and exclusion criteria 
 
Table S1. Inclusion- and exclusion criteria 
Inclusion criteria for patients 
1) Able to provide informed consent 
2) Genetically proven DM1, aged 18 years and older, suffering from severe fatigue (CIS-fatigue subscale score ≥35). The genetic 
diagnosis and level of fatigue were determined as part of the eligibility screening process 
3) Ability to walk independently (ankle-foot orthoses and canes accepted) 
Exclusion criteria for patients 
1) Neurological or orthopedic co-morbidity interfering with the interventions or possibly influencing outcomes 
2) Use of psychotropic drugs (except modafinil, methylphenidate and antidepressants where the dosing regimen has been stable for at least 
12 months prior to screening). If the doses of modafinil or methylphenidate increase during the 10 months of intervention/non-
intervention, then the patient will be excluded 
3) Severe depression at screening as per clinical judgement 
4) Participation in another clinical trial of an investigational medicinal product (CTIMP) or other interventional study considered to 
influence outcomes being evaluated in OPTIMISTIC concurrently or within 30 days prior to screening for entry into this study 
5) Unable to complete study questionnaires 
Inclusion criteria for caregivers 
1. Ability to give informed consent 
2. Ability to complete study questionnaires 
3. Ability to attend CBT sessions with patients 
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Table S2. Description of standard care in the four different clinical sites 
 
Brief name  Standard care 
Why Regular follow-up 
Every patient received standard care as to local neuromuscular care practice prior, during and after conduct 
of the study. Standard care aims to monitor disease progression, ameliorate symptoms and prevent or treat 
DM1 related complications. Here we provide an overview of what constitutes standard care in these four 
countries, and highlight differences in practice between them. 
 
Physiotherapy 
Assessment of patients by physiotherapists is common in all countries, but significant between country 
differences exists. Physiotherapy addresses functional deficits, fall prevention, orthotics, respiratory 
problems and pain in DM1 patients. Its goals are to maintain functionality and participation. The intensity 
(number and duration of contact moments) of physiotherapy vary between countries. 
What (materials) Treatment guidelines 
All centers provide standard care as per local protocols and guidelines. 
Munich Germany: Local care protocol; no national guideline available 
Nijmegen, the Netherlands: Local care protocol, based on multidisciplinary treatment guideline, which is 
available from: https://richtlijnendatabase.nl/richtlijn/myotone_dystrogie_type1/myotone_dystrofie_type1_-
_korte_beschrijving.html. 
Paris, France: Local care protocol; no national guideline available 
United Kingdom: Local care protocol, no national guideline available 
 
Information for patients 
Patient education and information is digitally provided by patient groups at all  four sites. These sites also 
provide information for the physiotherapists. 
France: 
https://www.afm-telethon.fr/maladie-steinert-1175 
Germany:  
https://www.dgm.org/muskelerkrankungen/myotone-dystrophie-typ-1 
the Netherlands:  
https://www.spierziekten.nl/overzicht/myotone-dystrofie   
UK: 
http://www.myotonicdystrophysupportgroup.org/ 
 
Screening questionnaires might include 
• Fatigue and daytime sleepiness 
Fatigue and daytime sleepiness scale (FDSS), Epworth sleepiness scale (ESS), Checklist individual strength-
subscale fatigue (CIS-fatigue). 
• Mood disorders 
Beck depression inventory (BDI) 
 
What (procedures) All participating centers offer specialized multidisciplinary neuromuscular care. This involves regular 
follow-up for every patient at the outpatient clinic in the specialized neuromuscular center. For each patient, 
a neurologist and/or rehabilitation specialist, specialized nurse and research physiotherapist is involved. 
Assessments are organized on the same day if feasible. Involvement of other care professionals is dependent 
upon the needs of the patient. Coordination of care is the responsibility of the neurologist or rehabilitation 
specialist. 
 
Cardiac care involves annual or bi-annual cardiac consultation and yearly ECG control with additional 
diagnostics as needed. Pulmonary care involves yearly respiratory function tests in all patients, with referral 
to a pulmonary specialist if indicated.  
Who provided Regular follow-up 
Multidisciplinary care is usually coordinated by a neurologist or rehabilitation specialist who is supported by 
a specialist nurse. The different aspects of multidisciplinary care are provided by the respective care 
professionals: 
• Medical specialty care: cardiology, respiratory, gynecology, gastro-enterology and medical 
genetics 
• Paramedical care: physiotherapy, speech therapy, occupational therapy 
• Psychological and other care: occupational attention and social support, (medical) psychology  
All professionals involved have experience in caring for patients with neuromuscular disorders and are 
connected within the network that the specialized neuromuscular center provides. 
 
Physiotherapy 
Munich, Germany: Physiotherapists of occupational therapists at hospital or in local settings. 
Nijmegen, the Netherlands: Physiotherapists of neuromuscular care unit or locally working physiotherapists 
Paris, France: Occupational therapists of neuromuscular care unit and locally working physiotherapists 
Newcastle, UK: Physiotherapists or physiotherapist assistants of the neuromuscular care unit 
 
How Regular follow-up 
Annual neurologic or rehabilitation visits are usually in a face-to-face format. Follow-up appointments may 
be via telephone or internet. 
 
Physiotherapy  
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Physiotherapy is provided face-to-face, normally in single person sessions and rarely in group therapy. It is 
often provided by a local physiotherapist (e.g. working in the vicinity of the patient’s home) 
Where Regular follow-up 
Regular follow-up is in the setting of the specialized neuromuscular care unit of  the hospital. 
 
Physiotherapy 
Munich, Germany: Physiotherapy is provided at the hospitals or at local physiotherapy and occupational 
therapist centers. 
Newcastle, UK: Physiotherapy is provided at neuromuscular care units in hospital settings throughout the 
UK 
Nijmegen, the Netherlands: Physiotherapy is provided at the neuromuscular care unit or at a local center for 
physiotherapy. 
Paris, France: Occupational therapy is provided at the neuromuscular care unit and physiotherapy at local 
physiotherapist centers.   
When  and  how 
much 
Regular follow-up 
Annual control visits that last 30 to 90 minutes constitute the minimum intensity of standard care. Additional 
or more frequent visits are planned if required, such as in the case of complications or progressive disease. 
Cardiac follow-up is annual at minimum.  
 
Physiotherapy 
Munich, Germany: Physiotherapy is provided at least once a week, twice a week for most patients for 20 
minutes each session. 
Newcastle, United Kingdom: Visits are scheduled annually as standard and last for approximately 30 
minutes. When required, additional visits may be scheduled. 
Nijmegen, Netherlands: Physiotherapy is provided once a week at minimum for 20 to 30 minutes per 
session. 
Paris,  France: Physiotherapy is provided once a week or twice a week for most patients for 20 minutes per 
session.  
Tailoring Regular follow-up 
An individual care plan is made for every patient on the basis  of screening for symptoms, signs and 
complications known to occur in DM1. Screening is based on nurse and physician anamnesis, sometimes 
supported with patient reported questionnaires. Particular attention is given to the presence of cardiac or 
respiratory complications. 
 
Physiotherapy 
Physiotherapy recommendations are tailored to the individual according to specific needs and functional 
deficits. In addition, the physiotherapy may vary as consequence of local variations in physiotherapy 
practice. 
Modifications Local protocol and guidelines for standard care may be updated upon availability of new evidence on 
interventions. No relevant changes or updates were made during the conduct of the trial. 
How well At every study assessment, it was recorded whether concomitant therapies were given as part of standard 
care. 
Table S2. Table describing standard care according to TIDieR checklist and guide.4  
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Table S3. Description of Cognitive behavioural therapy (CBT) 
 
Brief name  Cognitive behavioural therapy (CBT) 
Why CBT was based on a  model of determinants of disease burden in DM1. This model predicted that to 
improve patient reported health status and thus reduce disease burden, treatment should aim to compensate 
for a reduced initiative, alleviate experienced fatigue, optimize the interaction with caregivers, and increase 
activity and social participation. CBT has been shown to be effective to improve health status in other 
chronic diseases. 
What All patients started with psycho-education and goal formulation. Patients were then offered a tailored CBT 
intervention consisting of a maximum of six modules: 1) Learning to compensate for a reduced initiative; 2) 
Optimize social interactions with caregivers;3) Regulation of sleep-wake pattern; 4) Reformulation of 
dysfunctional beliefs with respect to fatigue or DM1; 5) Activity regulation and graded activity; 6) Coping 
with pain.  
Which modules were administered was decided on the basis of an assessment and intake. During every 
session, one or several treatment modules were discussed. At the end of every session, ‘homework’ 
exercises were discussed with the patient. During the first CBT session (‘intake’) therapist and patient 
decided if exercise therapy would be added to the graded activity of CBT. Graded exercise commenced if 
patients successfully increased their level of physical activity during the graded activity module. Only two 
sites provide graded exercise. All patients completed CBT with step by step realization of treatment goals.  
Therapists delivered the CBT according to a detailed manual (available on request from H Knoop: { 
HYPERLINK "mailto:hans.knoop@amc.uva.nl" }), which was specifically designed for this 
study. The intervention was delivered in face-to-face sessions or sessions via telephone of skype. Patients 
could also correspond via email with their therapist. The exercise module of the intervention was delivered 
by a physical therapist in cooperation with the CBT therapist. Patients were provided with a workbook that 
provided information on the disease and CBT. In addition, the workbook was used to document treatment 
goals, record progression and identify potential problems.  If possible, CBT also involved the caregiver of 
the patient to help the patient in achieving the treatment goals. 
 Essential in CBT was that by interaction with the patient, his/her thoughts were changed and behaviour was 
altered in such a way that health status was improved.  CBT focused mainly on three common and 
debilitating symptoms in DM1: (1) chronic fatigue, (2) reduced initiative and (3) lack of and/or negative 
social interactions. It was assumed that the level of physical activity and social participation could be 
increased if the afore mentioned problems were addressed. A graded activity program, with exercise added 
if appropriate, was thought to be an important element of the intervention in order to reduce fatigue and 
increase activity and participation.  
Who provided Over the four participating centers, 10 cognitive behavioural therapists delivered the intervention. They 
received a three day training program prior to the start of the trial with weekly or biweekly supervision 
during the trial. 
How CBT sessions were delivered to the individual patients. We aimed for a minimum of five face-to-face 
sessions. Other communication formats, such as telephone, or video-conferencing were acceptable. 
Appointments for the next session were made at the end of the session. 
Where In some clinical sites, CBT was delivered in the same location where the assessment took place. In other 
centers, delivery was in a different location remote from the clinical site. If sessions were delivered 
remotely, the patients could stay at home or alternatively be  at work or elsewhere. 
When  and  how 
much 
CBT was started immediately after randomization and baseline assessment. CBT session were divided into 1 
to 3 week windows, with a maximum of 14 sessions over a 10-month period, with the majority of sessions 
delivered in the initial four months. There was no minimum duration of sessions, but anticipated duration 
was between 15 and 75 minutes depending on the communication format. 
Tailoring CBT was tailored to the individual patient. At the start of therapy, each patient underwent baseline CBT 
screening with self-reported questionnaires. On the basis of cut-off scores, it was then determined which 
CBT modules were indicated and these were planned to be delivered during therapy.3 Additional modules 
could be added by the therapist on the basis of the intake session if deemed necessary. The duration of 
therapy and communication format were determined by shared decision making between therapist and 
patient. 
Modifications No modifications to CBT were made during the conduct of the trial. 
How well Throughout the period in which CBT was given, there was remote supervision for all therapists by two 
experienced CBT therapists who had been involved in the design of the manual. Any difficulties or 
problems were discussed. 
 
At the end of every session, the therapist recorded the number, duration, communication format, whether the 
caregiver attended and which modules had been addressed during the session on a predesigned CBT case 
report form (CRF). This information was later used by independent assessors to determine whether the 
delivered CBT was in accordance with the protocol and the scheduled contents of therapy as determined by 
the baseline CBT screening. In addition, a proportion of the sessions were recorded for purpose of later 
assessment of treatment integrity. These sessions were rated by independent assessors with the help of a 
previously designed, piloted and adjusted rating form. 
 Participants received an average of 9.0 (SD 3.2) hours of CBT divided over an average of 10·7 (SD 3.3) 
sessions. For patients allocated to CBT for which the information was available (N = 119), the different 
modules were given in the following numbers: (1) regulating sleep wake rhytm: 116 (97.5%), (2) 
compensating for reduced initiative: 109 (91.6%), (3) activity regulation and graded activity: 112 (94.1%), 
(4) reformulation of dysfunctional beliefs with respect to fatigue or DM1: 98 (82.4%), (5) optimize social 
interactions with caregivers: 79 (66.4%), (6) coping with pain 19 (16.0%). 
 
73 (61.3%) participants had their caregiver involved in the study. An average of  6.3 (SD 4.0) sessions was 
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given in face-to-face communication format. 70 participants (58.8%) had at least 5 face-to-face sessions. 
For an extended analysis of CBT treatment integrity, we refer to supplement S8. 
Table S3. Table describing cognitive behavioural therapy according to TIDieR checklist and guide.4 A more 
detailed description has been published previously.3  
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Table S4. Description of graded exercise 
  
Brief name  Graded exercise 
Why To increase patient’s activity levels on a graded, structured and guided manner. In DM1, exercise therapy 
has been shown to be feasible and safe, and suggestions of impact on disease burden have been made, 
although efficacy remains to be demonstrated. 
What The need for an exercise program was defined through the CBT therapist counseling and aimed to 
incorporate moderate intensity exercises such as walking, cycling, jogging or dancing. 
 In both Newcastle and Nijmegen, main activities of GET were outdoor or indoor cycling, outdoor walking, 
swimming and cardio fitness at a fitness center. 
Who provided Physiotherapists with experience in DM1.  
How First visit aimed to define: 1) exercise concept, 2) graded exercise goals, 3) graded exercise program and 4) 
identification of any possible barriers. It was always face-to-face with a minimum duration of one hour. 
Follow-up assessments were allowed to be performed by phone, or video-conferencing or face-to-face.  
Each patient received a graded exercise diary to record: 1) form of exercise recommended and practiced, 2) 
duration and frequency of training, 3) sessions per week and, 4) either heart rate measurement or the score of 
perceived exertion (BORG scale) after each training session, and, 5) any comments on their experience with 
the program. These diaries were part of the CBT workbooks. These were reviewed and discussed with the 
physiotherapist in charge at every follow-up assessment and appropriate modifications were made. 
Where Graded exercise were only implemented in Newcastle (UK) and Nijmegen (Netherlands).  
The first graded exercise session was delivered at clinical site/hospital in both Nijmegen and Newcastle. In 
Nijmegen, follow-up appointments were held primordially by telephone, whereas in Newcastle, some 
participants preferred face-to-face sessions. Participants were free to choose the locations for them to 
exercise, including but not limited to: their homes, local fitness centers, dancing schools or hospital 
physiotherapy facilities. 
When  and  how 
much 
The graded exercise module was incorporated within the months of the CBT intervention (i.e. 10 months 
after randomization). This module was offered after patients had increased their activity levels as part of the 
standard graded activity module and had reached the established goals for this module. The option for 
further activity increment was either expressed by the participant or suggested by the CBT therapist.  
Exercise was recommended for at least half an hour, three times a week with the maximum dose based on 
the physiotherapists’ clinical judgment.  
Tailoring Exercise type and recommendations were tailored to each patient’s disease and demographic characteristics. 
The program could change or increase at every follow-up assessment as a shared-decision process between 
patient and physiotherapist. 
Modifications No modifications to the protocol for the graded exercise module were made during the conduct of the trial. 
How well There was no pre-defined number of sessions for the graded exercise module; however, compliance was 
considered when a minimum of one baseline session plus a follow-up verifying patient’s involvement was 
completed. 
 Together, 58 patients at Newcastle and Nijmegen were randomized to the intervention, of whom 33 were 
recommended for the graded exercise program. There were two losses in follow-up from this module due to 
lack of compliance with the program. The median [IQR] duration of exercise practice was 127 [79] minutes 
a week per patient.  
Table S4. Table describing graded exercise therapy according to TIDieR checklist and guide.4 A more detailed 
description has been published previously.3. 
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Table S5. Overview of primary and secondary outcome Measures 
 
Table S5. Overview of primary and secondary outcome measures 
Name and Reference (abbreviation) Score range What is measured Direction of Score Notes 
Primary Outcome     
DM1-Activ-c1,2 (DM1-Activ-c) 0 to 100 capacity for activity and 
participation 
higher scores are beneficial Independent conversion of raw data at Maastricht University Medical Centre, 
Maastricht, the Netherlands 
Secondary Outcomes    No conversion was done, analysis of raw data 
Six-minute walk test5,6 (6MWT) 
BORG scale 
0 to ∞ 
0 to 10 
exercise capacity 
perceived exertion 
higher scores are beneficial 
lower scores are beneficial 
 
Taken after completion of the 6MWT 
Myotonic Dystrophy Health Index7,8 
(MDHI) 
0 to 100 impact of disease lower scores are beneficial Independent conversion of raw data at Rochester University, Rochester, USA 
Fatigue and Daytime Sleepiness Scale9 
(FDSS) 
0 to 100 experienced fatigue and 
sleepiness 
lower scores are beneficial Independent conversion of raw data at Maastricht University Medical Centre, 
Maastricht, the Netherlands 
Checklist Individual Strength – subscale -
fatigue10 (CIS – fatigue) 
8 to 56 experienced fatigue lower scores are beneficial No conversion was done, analysis of raw data 
 
 
Accelerometry 0 to ∞ activity higher scores are 
beneficial/indicate higher activity 
levels 
No conversion was done, analysis of raw data 
Individualized Neuromuscular Quality of 
Life Questionnaire – domain quality of 
life11 (INQoL) 
0 to100% quality of life/ health status lower scores are beneficial No conversion was done, analysis of raw data 
Beck Depression Inventory – fast 
screen12,13 (BDI – FS) 
0 to 21 depression lower scores are beneficial No conversion was done, analysis of raw data 
Apathy Evaluation Scale – clinical 
version14 (AES – c) 
18 to 72 apathy lower scores are beneficial No conversion was done, analysis of raw data 
Stroop color-word interference score 
(Stroop interference) 
0 to ∞ executive cognitive 
functioning 
lower scores are beneficial No conversion was done, analysis of raw data 
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Table S6a. Mixed model primary analysis and tests of pre-specified subgroup differences for primary outcome 
DM1-Activ-c 
 
Primary Analysis Adjusted* Regression 
Coefficient (95% CI) 
p-value 
   
Behavioural Intervention vs Standard 
Care 
3·27 (0·93 to 5·62) 0·007 
   
Intervention (Behavioural 
intervention vs Standard care) by 
Subgroup Analyses  
Adjusted* Regression 
Coefficient (95% CI) 
p-value 
   
Intervention x age -0·166 (-0·373 to 0·041) 0·117 
   
Intervention x gender (female/male) 5·996 (1·592 to 10·399) 0·014 
   
Intervention x site Overall† 0·330 
   
Intervention x site (Paris as 
comparator) 
Individual Sites  
   
Intervention Munich (vs. Paris)^  -0·065 (-4·738 to 4·608) 0·978 
Intervention Newcastle (vs. Paris)^  3·212 (-1·808 to 8·231) 0·212 
Intervention Nijmegen (vs. Paris)^ -0·773 (-5·599 to 4·054) 0·754 
Standard Care Munich (vs. Paris)^ -1·895 ( -6·567 to 2·777) 0·428 
Standard Care Newcastle (vs. Paris)^ -1·087 (-6·106 to 3·933) 0·672 
Standard Care Nijmegen (vs. Paris) ^ -4·807 (-9·524 to -0·090) 0·047 
   
Intervention by MIRS 0·404 (-2·341 to 3·149) 0·773 
   
Intervention x Caregiver (Y/N) 2·114 (-2·651 to 6·878) 0·385 
   
Intervention x (CBT alone / CBT 
+graded exercise) 
1·5100 (-1·904 to 4·924) 0·388 
   
Intervention x No. of CBT sessions 0·1172 (-0·275 to 0·509) 0·559 
   
Table S6a. Mixed model primary analysis and tests of pre-specified subgroup differences for primary 
outcome DM1-Activ-c 
Since none of interactions was significant at the level corrected for multiple testing of p<0·004 (p = 0·05/ 13), 
the presented regression coefficients should be considered resulting from ‘post-hoc’ analyses. 
*Adjusted for Baseline value, MIRS, Site, Carer (Yes, No) and Age.   
†  Test of Intervention effect by site over all sites 
^ Test for interaction of site with treatment allocation (intervention versus standard care) on outcome, with Paris 
as  arbitrarily chosen comparator 
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Table S6b. Subgroup analyses for all (primary and secondary) outcome measures 
 
Table S6b. Pre-specified subgroup analysis at 10-month follow-up. 
  Treatment by subgroup interaction Intervention Alone^ 
Outcome Adjusted* 
model-
Treatment  
Age Sex Site  MIRS Caregiver CBT alone 
vs CBT 
+graded 
exercise 
Number of 
CBT 
sessions 
 p-value p-value p-value p-value p-value p-value p-value p-value 
Primary 
outcome 
        
DM1-activ 0·007 0·117 0·014 0·330 0·773 0·385 0·388 0·559 
         
Secondary 
outcomes 
        
Total distance 
(m) in 6 MWT 
0·0009 0·221 0·784 0·026 0·074 0·622 0·298 0·092 
         
MDHI 0·144 0·795 0·376 0·014 0·169 0·733 - - 
         
Acceler.† 
(mean activity) 
0·0005 0·056 0·681 0·408 0·026 0·582 0·273 0·454 
         
Acceler.†  (5 
hours of highest 
activity) 
0·005 0·091 0·888 0·138 0·039 0·485 0·271 0·494 
         
Acceler.†  (5 
hours of lowest 
activity) 
0·141 0·342 0·673 0·695 0·511 0·188 0·980 0·268 
         
FDSS 0·0002 0·277 0·730 0·0002 0·412 0·237 - - 
         
CIS – fatigue 0·001 0·859 0·432 0·011 0·375 0·709 0·003 0·170 
         
INQOL– QOL 
domain 
0·196 0·037 0·639 0·038 0·220 0·880 0·254 0·133 
         
BDI-FS, log 
transformed  
0·859 0·769 0·494 0·039 0·876 0·140 0·715 0·088 
         
AES-c 0·444 0·470 0·429 0·002 0·064 0·618 0·004 0·003 
         
Stroop Score 
(log 
transformed)  
0·389 0·021 0·851 0·006 0·858 0·087 0·421 0·958 
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Table S6b. Pre-specified subgroup analysis at 10-month follow-up. 
*adjusted for baseline value, MIRS, site, cares (yes/no) and age 
† N=143 who completed accelerometry.  
For 84 tests in total, p<0·0006 indicates corrected statistical significance; one of the statistical tests reached 
significance: values indicated in bold are significant.  
^ In case of empty cells, the model was unable to calculate the estimates. This could be due to lack of data or 
small numbers in cells. 
 
Abbreviations: 6MWT: six-minute walk test; AES apathy evaluation scale; BDS-FS: Beck depression inventory 
– fast screen; CIS-fatigue: checklist individual strength – subscale fatigue; InQoL: individualized neuromuscular 
quality of life; MDHI: myotonic dystrophy health index; MIRS: muscular impairment rating scale; Stroop: 
Stroop color-word interference test. 
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Table S7. Repeated measures analysis for primary and secondary outcomes 
 
Table S7. Repeated measures analysis for primary and secondary outcomes 
Outcome Treatment arm  Baseline 5 months 10 months 16 months Repeated 
measures* 
Primary 
outcome 
 N Mean (SD)  N Mean 
(SD) 
N Mean 
(SD) 
N Mean 
(SD) 
Overall 
difference (se) 
DM1-activ-c Intervention 
group 
128 61·22 
(17·35) 
120 63·50 
(19·30) 
115 63·92 
(17·41) 
107 62·57 
(18·18) 
2·87 (0·99), 
p = 0·004 
 Standard care 
group 
127 63·00 
(17·35) 
104 62·75 
(17·74) 
116 60·79 
(18·49) 
105 62·31 
(17·30) 
           
Secondary 
outcomes 
          
Total distance 
(m) in 6MWT 
Intervention 
group 
128 389·3 
(123·2) 
113 419·35 
(124·1) 
111 420·65 
(134·8) 
97 413·10 
(131·0) 
25·9 (6·4),  
p < 0·001 
 Standard care 
group 
127 400·7 
(119·7) 
101 397·54 
(122·6) 
99 401·10 
(133·5) 
94 400·78 
(131·7) 
           
MDHI Intervention 
group 
128 37·49 
(18·33) 
117 31·46 
(20·25) 
112 31·78 
(19·35) 
103 33·28 
(19·42) 
-2·32 (1·37), p 
= 0·090 
 Standard care 
group 
127 35·64 
(16·08) 
103 32·63 
(17·67) 
106 33·05 
(17·72) 
104 31·54 
(17·15) 
           
FDSS Intervention 
group 
128 45·9  
(9·7) 
115 39·4 
(10·8) 
110 38·4 
(10·3) 
105 39·8 
(11·6) 
-3·50 (0·99), p 
< 0·001 
 Standard care 
group 
127 46·6 (11·5) 110 43·9 
(10·7) 
104 43·2 
(10·8) 
102 42·7 
(10·1) 
           
CIS – Fatigue Intervention 
group 
128 44·89 
(5·92) 
120 36·73 
(10·03) 
113 36·27 
(10·91) 
107 38·59 
(11·22) 
-3·46 (0·99), p 
< 0·001 
 Standard care 
group 
127 44·88 
(6·34) 
104 41·23 
(8·64) 
106 40·62 
(8·46) 
105 40·29 
(8·75) 
           
Acceler.† 
(Mean activity) 
Intervention 
group 
128 19·92 
(9·53) 
77 21·27 
(9·61) 
88 21·22 
(9·91) 
63 20·28 
(9·41) 
1·87 (0·73), p = 
0·011 
 Standard care 
group 
127 21·33 
(12·72) 
77 19·19 
(9·88) 
76 19·32 
(8·85) 
76 19·02 
(10·72) 
           
Acceler.† (5 
hours of highest 
activity) 
Intervention 
group 
128 48·80 
(26·19) 
77 53·57 
(27·63) 
88 53·60 
(29·93) 
63 49·77 
(26·91) 
5·20 (2·08), p = 
0·013 
 Standard care 
group 
127 51·01 
(34·56) 
77 46·42 
(28·53) 
76 47·21 
(24·93) 
76 46·56 
(30·53) 
           
Acceler.† (5 
hours of lowest 
activity) 
Intervention 
group 
128 3·86 
(0·79) 
77 3·96 
(1·08) 
88 3·88 
(0·78) 
63 3·80 
(0·68) 
0·10 (0·10), p = 
0·297 
 Standard care 
group 
127 4·29 
(2·38) 
77 3·89 
(1·06) 
76 3·80 
(0·66) 
76 3·73 
(0·65) 
           
BDI-FS  Intervention 
group 
128 4·31 
(3·10) 
117 3·88 
(3·42) 
110 4·06 
(3·44) 
104 3·96 
(3·11) 
0·003 (0·020), 
 p = 0·888 
 Standard care 
group 
127 4·03 
(3·15) 
103 3·33 
(2·91) 
105 3·60 
(3·14) 
103 3·33 
(3·03) 
           
AES-c Intervention 
group 
128 38·87 
(9·07) 
111 36·94 
(8·51) 
109 36·31 
(8·47) 
105 38·08 
(8·91) 
-1·31 (0·70), p 
= 0·061 
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 Standard care 
group 
127 37·33 
(8·65) 
101 37·80 
(9·42) 
103 37·24 
(9·84) 
101 36·72 
(8·65) 
           
Stroop Score  Intervention 
group 
128 92·19 
(72·26) 
117 77·96 
(41·57) 
115 73·95 
(40·15) 
106 71·98 
(37·49) 
-0·0002 (0·04),  
p = 0·996 
 Standard care 
group 
127 90·27 
(51·99) 
99 77·09 
(39·82) 
105 77·75 
(51·41) 
104 68·15 
(34·48) 
           
INQOL– QoL 
domain 
Intervention 
group 
128 78·14 
(31·94) 
119 70·17 
(36·93) 
113 69·21 
(35·95) 
104 72·03 
(37·66) 
-3·62 (2·90), p 
= 0·212 
 Standard care 
group 
127 72·72 
(34·82) 
103 68·50 
(33·78) 
105 70·26 
(34·80) 
104 69·32 
(34·20) 
           
Table S7. Overview of raw scores per allocation group for all primary and secondary outcomes at all 
timepoints 
The numbers indicate the number of participants available analysis at each time point for the outcome measure. 
*Repeated measures for overall difference are adjusted for age, baseline, MIRS, involvement of a caregiver, 
clinical site and visit. 
Abbreviations: 6MWT: six-minute walk test, FDSS: fatigue and daytime sleepiness scale; CIS-fatigue: checklist 
individual strength, subscale fatigue, Accel: accelerometry, BDI-FS: Beck depression inventory, fast screen; 
AES-c: apathy evaluation scale, clinician version; Stroop: Stroop interference score; InQoL: individualized 
neuromuscular quality of life questionnaire – quality of life domain 
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S8. Analysis of treatment integrity 
Methods 
Description of the intervention 
In OPTIMISTIC, 128 out of the recruited 255 severely fatigued DM1 patients were randomised to receive a 
behavioural intervention from April 2014 to May 2015. There were four treatment sites: Nijmegen, the 
Netherlands (n=33);  Munich, Germany (n=33);  Paris, France (n=37) and Newcastle, UK  (n=25). All patients 
allocated to intervention received CBT with added GET in a subset of patients (33 out of 128, 26%). We here 
outline the general structure of CBT, a more detailed description is available in the published protocol paper of 
the OPTIMISTIC study. CBT focused on three common and debilitating problems in DM1: chronic fatigue (1), 
reduced initiative (2) and a lack in social interactions and negative interactions (3). All patients started with 
psycho-education and goal setting.  There were 6 treatment modules:  regulating sleep-wake pattern (1), 
compensating for a reduced initiative (2), graded activity with an optional graded exercise therapy (GET) add-on 
(3), formulating helpful beliefs about fatigue and MD (4), optimizing social interactions (5) and coping with pain 
(6). The contents (modules) of CBT were individualised on the basis of the baseline assessment consisting of 
questionnaires, actigraphy and a clinical interview at the start of CBT. At baseline it was determined which 
modules were indicated. The questionnaires and their cut-off scores used to tailor therapy to the individual 
patient are listed below. 
Module Module Instrument Score whereby specified 
module is selected 
 Psychoeducation and 
goal setting 
None Always indicated 
1. Regular sleep-wake 
rhythm 
- Registration: overview of 
sleep/wake rhythm over 12 days 
- Sickness Impact Profile (SIP) 
subscale sleep & rest 
Visual inspection by 
therapist 
 
Score ≥ 60 
2. Compensating for 
reduced initiative 
- Apathy evaluation Scale – 
clinician version (AES-c) 
Score >38 
3. Activity None  Always indicated 
4. Helpful thoughts about 
fatigue and DM 
Cognitions about fatigue 
- Jacobsen Fatigue Catastrophing 
scale (FCS) 
- SES-28 fatigue 
- IMQ-focus on fatigue 
 
Cognitions about DM1 
- Pictorial Representation of Self 
and Illness measure (PRISM) 
 
- Beck Depression Inventory (BDI-
II-PC) 
- Illness Cognition List subscale 
acceptance 
 
Score ≥ 16 
 
Score ≤ 19 
Score ≥ 30 
 
 
The DM causes more 
suffering than the fatigue, 
measured in lower 
distance in cm from the 
person 
Score ≥ 4 
 
Score ≤ 12 
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5. Optimising the 
interactions with direct 
environment 
Interaction with close others 
- Caregiver strain index (CSI) 
- Marital satisfaction VAS 
 
Experienced social support 
Social Support Inventory 
- Subscale Discrepancy (SSL-D) 
- Subcale Negative Interactions 
(SSL-N) 
 
Score ≥ 7 
One of partners ≤ 60 mm 
 
 
 
Score ≥ 53 
 
Score ≥ 11 
6. Managing pain McGill Pain Questionnaire (MPQ) 
 
SF-36 Pain 
Score ≥ 44 
 
Score ≤ 60 
Supplementary table S8-1: Treatment modules and their indication according to baseline quantitative 
questionnaires 
  
Participants could opt for the GET module, a structured exercise program aimed at further gradually increasing 
physical activity levels and fitness goals from those set and already reached as part of the graded activity 
module. This module would be offered when a participant formulated goals that asked for a more structured 
exercise program and when they reached a satisfactory activity performance on their graded activity module that 
could allow the implementation of an exercise routine (i.e. already walking or cycling a minimum total of 30 
minutes 3 to 5 times per week).  The overall intervention (i.e. CBT and GET when applicable) had a duration of 
10 months. The treatment protocol described that the majority of CBT sessions should be delivered in the first 4-
5 months, with a total maximum of 14 sessions. There was no pre-defined number of sessions for the GET 
module; however, compliance was considered when a minimum of one baseline session plus a follow-up 
verifying patient’s involvement was completed. 
 
CBT therapists and training 
Ten licensed CBT therapists, all but one also psychologists, delivered the intervention in the 4 treatment centres. 
None of them had prior experience with delivering CBT in patients with DM1 and most of them had also no 
experience with treating patients with a somatic illness. Prior to start of the study, 12 therapists were given a 3-
day training followed by a skills test. Eleven of them passed the test. Therapists were given weekly or biweekly 
supervision by telephone delivered by HK, SB and SvL. One therapist left the study before the end of CBT. 
 
Analysis of treatment delivery for CBT and GET 
At each CBT session, the therapist filled out a case rerport form (CRF) from which the following variables were 
calculated for each participant: total number of CBT sessions, total session time in minutes, number of sessions 
delivered in face-to-face communication format, number of sessions in which the caregiver attended, which 
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modules were delivered during treatment, and the number of sessions that were given within the first four 
months of treatment. Patients randomized to treatment who never started therapy or had ≤2 sessions were 
considered drop-outs and excluded.  
 
In addition to the CRFs recorded by the therapists information on treatment delivery was provided by, a 
proportion of  CBT sessions that had face-to-face or Skype communication format and were audio recorded. 
Three assessors involved in the study but not with intervention delivery, were trained to rate CBT sessions by an 
experienced CBT therapist who was involved in the design of the treatment manual. A subset (11%) of randomly 
selected audio recorded sessions were rated, after stratification to obtain a representative sample of tapes based 
on treatment centre, sessions number and sessions given early versus late during the trial. We evaluated for each 
session the behaviour of the therapists, if the workbook was used and if  homework assignments were discussed.  
On a Likert scale therapist behaviour was scored if the therapist had discussed the modules as indicated on the 
CRF. Scores could range from ‘not dealt with’(score 0) to ‘excellent concordance with treatment manual’ (score 
5), for which evidence of changed patient cognitions and concrete behavioural goals had to be demonstrated. We 
considered a score of  ≥ 3 ‘adequate’ for the module that was evaluated. The first eight Dutch sessions to be 
analysed were double-rated in order to assess the interrater reliability by means of intraclass correlation 
coefficients (ICCs).  The module with the lowest ICC still had a moderate interrater-reliability (ICC equal to or 
higher than .50) and the mean was .83 which is a good interrater-reliability.16 All remaining sessions were rated 
by one rater. 
 
Criteria for CBT treatment integrity 
We predefined a set of criteria for treatment integrity based on the treatment manual: (1) Was CBT delivered 
according to protocol in terms of frequency of contact and communication format?  (2) Are the CBT treatment 
modules as given? (3) Was treatment content accoding to protocol? Regarding the first criterion, the required 
minimum of sessions was 10, with a minimum of 5 face-to-face sessions For the second criterion, the modules 
delivered by the therapist according to the CRFs were compared with the indicated modules at baseline 
screening, requiring a 100% overlap (100% of indicated sessions given). For the third criterion, we calculated the 
number of CBT modules that were scored  ≥3 in the audio recorded sessions. 
 
Results 
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Cognitive behavioural therapy: case report form analysis 
Treatment delivery in OPTIMISTIC  
Criterion 1 (CRF)  
Number of participants randomised for intervention 128 
Number of participants in CBT analysis 119 
Average number of sessions of CBT per participant; - mean (SD) 10·7 (3·3) 
Average total duration of CBT per participant in hours - mean (SD) 9·0 (3·2) 
Average number of face-to-face sessions - mean (SD) 6·3 (4·0) 
Number of participants with  ≥ 10 sessions (% of participants) 82 (69) 
Number of participants with ≥5 face-to-face sessions (% of 
participants) 
70 (60) 
Number of sessions with ‘face-to-face’ or Skype communication 
format (% of total) 
837 (65·9) 
Criterion 2 (CRF)  
Number (%) of participants for whom psychoeducation and goal 
setting) was indicated/given 
119 (100) / 117 (98) 
Number (%) of participants for whom module 1 (sleep-wake rhythm) 
was indicated/given 
85 (71) / 116 (97) 
Number (%) of participants for whom module 2 (compensating for 
reduced initiative) was indicated/given 
73 (61) / 109 (92) 
Number (%) of participants for whom module 3 (activity) was 
indicated/given 
119 (100) / 112 (94) 
Number (%) of participants for whom module 4 (helpful beliefs) was 
indicated/given 
 105 (88) / 98 (82) 
Number (%) of participants for whom module 5 (social interactions) 
was indicated/given 
97 (82) / 79 (66) 
Number (%) of participants for whom module 6 (pain) was 
indicated/given 
56 (47) / 19 (16) 
Criterion 3 (audio recorded sessions)  
Number of taped sessions (as % of total number of sessions) 479/1270 (37·7) 
Number of rated sessions (as % of total numer of taped sessions) 55 (11·5) 
Number of modules dealt with in rated sessions 181 
Module rating – mean (SD) / median [IQR] 3.6 (1.1) / 4  [1] 
Number of modules rated ≥ 3 (% of total number of rated modules) 159 (87·8%) 
Supplementary Table S8-2 Summary of CRF recorded treatment delivery parameters. CBT cognitive 
behavioural therapy, GET graded exercise therapy. 
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Results for the analysis of the treatment delivery analysis are shown in table S8-2. For  119 out of 128 
participants, case report forms were available. For criterion 1, 82 (69%) of patients had  ≥ 10 sessions, and 70 
(60%) had ≥5 face-to-face sessions. With regards to the individual treatment modules, modules 1 (sleep-wake 
rhythm) and 2 (compensating for reduced initiative), were both less often indicated than given, 71·4 and 61·3 
percent versus 97·5 and 91·6 percent respectively (see table S8-2). In contrast, modules 4 (helpful beliefs), 5 
(social interactions) and especially 6 (pain) were more often indicated on the basis of intake than given during 
cognitive behavioural therapy: 88, 82 and 47 versus 82, 66 and 16 percent, respectively. We rated a total of 55 
sessions, 11·5 percent of the 479 taped sessions (table S8-2). In those 55 sessions, there were 181 modules that 
were dealt with. Of these, 159 modules (87.8%) were rated ≥ 3. 
 
Graded exercise therapy 
GET was only implemented two out of  four  treatment sites (Nijmegen and Newcastle). Forty-two participants 
considered suitable for the GET program were referred by CBT therapist to physical therapists. Nine patients 
were unable  to comply with the program requirements, due to insufficient motivation or inability to satisfy the  
aerobic exercise criterion (Appendix 2). Thirty-three participants officially started the GET program, of which 
31 were able to complete the program. One participant lost contact  with the physical therapist during GET, 
another participant withdrew from the study because of malignancy. In the first session, explanation of GET and 
its differentiation from  graded activity was given to all patients. Also, SMART defined goals were set and 
barriers for exercising identified. All but two patients started GET with a face-to-face intake sessions, after 
which there was either face-to-face or telephone follow-up. In both Newcastle and Nijmegen, main activities of 
GET were outdoor biking, outdoor walking, swimming and cardio fitness in a fitness center. Median duration of 
aerobic exercise per week was 126 minutes in Nijmegen and 170 minutes in Newcastle. 
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S9. Accelerometry 
 
Methods 
 
GENEActiv tri-axial accelerometers (ActivInsights Ltd, United Kingdom) were worn on the non-dominant ankle for 14 consecutive days at each visit. Accelerometer data 
was processed in R ({ HYPERLINK "http://www.cran.r-project.org" }) using R-package GGIR (R Foundation for Statistical Computing, Vienna, Austria; available from  { 
HYPERLINK "http://www.R-project.org/" }.{ HYPERLINK "https://cran.r-project.org/web/packages/GGIR/index.html" }).17,18 Default parameters with respect to 
the measures generates (ENMO, L5, M5), except where specified. Daily estimates of physical activity were calculated midnight to midnight. Signals were inspected and 
corrected for calibration error.19 Only days with at least 23 hours of valid data were included for data analysis. No imputation for missing values was used. The first and last 
day of the raw accelerometer measurement were excluded to avoid cofounding factors related to distribution or delivery procedures. Accelerometer data was only included in 
analysis if 7 days of valid data was available. The average magnitude of ankle acceleration was calculated via metric Euclidian Norm Minus One (ENMO) (millig, where 1mg 
= 0.001g = 0.001 x 9.8 m/s2 = 0.001 x gravitational acceleration). The average acceleration during the most active and least active 5 hour period of each day were also 
included for analysis (M5, L5). The difference between M5 and L5 provided a simple indicator of the level of circadian variability.20 
 
Table S9. Missing accelerometry data, non-compliance and device losses for each visit over the course of the study (%) 
 
Table S8. Data reflects the % of patient data that was not available for accelerometry analysis from those devices registered as received or returned to the site (^); Missing 
data: Inadequate data capture (data too small/not available); < 7 days of < 23 hours; Non-compliance: declined to wear device; device location misplacement (not worn on the 
ankle); daytime recording only.
 Baseline 5 months 10 months 16 months 
  Devices 
Received^ 
Missing 
data 
Non-
compliance 
Devices 
Received^ 
Missing 
data  
Non-
compliance  
Devices 
Received^ 
Missing 
data  
Non-
compliance  
Devices 
Received^ 
Missing 
data  
Non-
compliance  
% 84 10.7 2.3 86 9.8 4.7 82 9 4.2 83 4.5 4 
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